Asia/Oceania
Avistone Biotechnology to Launch Phase I Trial of c-MET Inhibitor in Canada
Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.
In Brief This Week: Modalis, Otsuka, CSL Behring, Papillon, Anixa Biosciences, PathAI
News items for the week of Sept. 30, 2024.
Cartherics Raises A$15M, Plans to Evaluate NK-Based Cell Therapy in Ovarian Cancer
With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.
Tessellate Bio Partners With Australian Research Institutes to Study ALT-Driven Cancers
The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.